Home  About us  Contact
 

E Patients (e + patient)

Distribution by Scientific Domains
Medical Sciences75%

Selected Abstracts

Hepatitis E antibody profiles in serum and urine

JOURNAL OF CLINICAL LABORATORY ANALYSIS, Issue 3 2002
M.S. Joshi
Abstract The aim of this study was to evaluate anti-HEV antibody profiles in urine specimens in comparison to corresponding serum samples to assess the utility of urine as a clinical specimen. Paired serum and urine specimens from 71 hepatitis E patients, 33 non-E hepatitis patients, 63 patients with nonhepatic diseases, and 26 healthy individuals were tested by recombinant HEV protein (55 kD)-based indirect enzyme-linked immunosorbent assay (ELISA). Uronegativity for anti-HEV IgM was noted in 71 (100%) serologically confirmed patients with hepatitis E. Hepatitis E patients (10/10) showed urinary absence or very low levels of total IgM by capture ELISA, suggesting absence or low levels of filtration, and/or local synthesis, and/or transudation of IgM in urine during infection. When these patients were tested for total IgG and IgA, microquantities of immunoglobulins were noted in all urine samples (10/10 for each). However, the proportions of uropositivity for anti-HEV IgG and IgA in hepatitis E patients were low and indicated only 21.42% and 49.33% concordance with seropositivity, respectively. Control groups also showed low and variable uropositivity for anti-HEV IgG and IgA. Overall, HEV-specific antibodies exhibited by serum in recent and past infections were not found in urine. The study demonstrated the inadequacy of urine specimens for detection of hepatitis E antibodies. J. Clin. Lab. Anal. 16:137,142, 2002. © 2002 Wiley-Liss, Inc. [source]

Acute glomerulonephritis in beta-thalassemia/haemoglobin E patients: A summary on Thai cases

NEPHROLOGY, Issue 1 2006
Viroj Wiwanitkit
[source]

A scoring system for the classification of ,-thalassemia/Hb E disease severity

AMERICAN JOURNAL OF HEMATOLOGY, Issue 6 2008
Orapan Sripichai
,-Thalassemia intermediate patients show a remarkable clinical heterogeneity. We examined the phenotypic diversity of 950 ,-thalassemia/Hb E patients in an attempt to construct a system for classifying disease severity. A novel scoring system based on six independent parameters, hemoglobin level, age at disease presentation, age at receiving first blood transfusion, requirement for transfusion, spleen size, and growth and development, was able to separate patients into three distinctive severity categories: mild, moderate, and severe courses. This system, therefore, can increase the accuracy of studies of genotype,phenotype interactions and facilitate decisions for appropriate patient management. Am. J. Hematol. 2008. © 2008 Wiley-Liss, Inc. [source]

Effect of coenzyme Q10 as an antioxidant in ,-thalassemia/Hb E patients

BIOFACTORS, Issue 1-4 2005
Ruchaneekorn W. Kalpravidh
Abstract Thalassemia is a group of genetic disorders resulting from different mutations in the globin gene complex and leading to an imbalance in globin synthesis. Unmatched globin chains are less stable and susceptible to oxidation. Patients with ,-thalassemia/HbE are prone to increased oxidative stress as indicated by increased lipid peroxidation product, malondialdehyde (MDA), partly because of the presence of iron in the form of heme and hemichromes released from excess globin chains and excess iron deposition in various tissues. The level of antioxidant such as glutathione is markedly decreased while activities of antioxidant enzymes including superoxide dismutase (SOD), catalase, and glutathione peroxidase (GSH-Px) are increased. We have recently found that the levels of coenzyme Q10 (CoQ10) are also very low in thalassemia. We therefore evaluated the oxidative stress and the antioxidants in these patients before and after supplementation with 100 mg CoQ10 daily for 6 months. The results showed that the plasma level of CoQ10 significantly increased and the oxidative stress decreased as the level of MDA declined. The administration of CoQ10 led to significant improvement of biochemical parameters of antioxidant enzymes. The antioxidant supplementation will be beneficial for thalassemia patients as adjunct therapy to increase their quality of life. [source]